02:09 , Jan 22, 2016 |  BC Extra  |  Financial News

bioMerieux spinout bioTheranostics raises $32M

bioTheranostics Inc. raised $32 million in an equity round and said it will spin out from parent company bioMerieux S.A. (Euronext:BIM). MVM Life Science Partners led the round, in which Canepa Advanced Healthcare Fund and...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Clinical News

Breast Cancer Index regulatory update

BioMerieux's Biotheranostics Inc. company said CMS posted a positive coverage and reimbursement policy for the Breast Cancer Index to determine the risk of early and late recurrence and benefit from extended endocrine therapy in patients...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Breast Cancer Index regulatory update

bioMerieux’s bioTheranostics Inc. company said the New York State Department of Health approved the company’s Breast Cancer Index (BCI) to determine the risk of early and late recurrence and benefit from extended endocrine therapy in...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

bioMerieux sales and marketing update

bioMerieux’s bioTheranostics Inc. subsidiary said U.S. healthcare provider FedMed Inc. will cover genomic tests for patients with breast cancer and metastatic cancers. bioTheranostics said that FedMed has a preferred provider network that includes more than...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Breast Cancer Index diagnostic data

Researchers at Massachusetts General Hospital and colleagues reported data from 665 postmenopausal women with estrogen receptor-positive breast cancer in a prospective comparative study showing that only the BCI predicts risk for both early (0-5 years)...
00:25 , Sep 13, 2013 |  BC Extra  |  Clinical News

Researchers compare diagnostics that predict breast cancer recurrence

Researchers at Massachusetts General Hospital reported data from a prospective comparative study showing that only Breast Cancer Index (BCI) from the bioTheranostics Inc. subsidiary of bioMerieux S.A. (Euronext:BIM) predicts risk for both early (0-5 years)...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

bioMerieux, GlaxoSmithKline deal

GlaxoSmithKline will co-fund bioMerieux's development of a pharmacogenetic test using undisclosed biomarkers for cancer. The CLIA test initially will be marketed by bioMerieux's bioTheranostics Inc. subsidiary, with development of an in vitro test kit to...
08:00 , Jan 5, 2009 |  BioCentury  |  Product Development

Intermediate decision-making

Oncotype DX from Genomic Health Inc. is used in over 50% of breast cancer patients to determine if they are at risk of recurrence and thus should receive chemotherapy following surgery. The problem is what...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

Theros Breast Cancer Index: Data

Data from tissue samples from 166 estrogen receptor-positive breast cancer patients showed that Theros Breast Cancer Index (BCI) reduced the number of patients classified as having an intermediate risk of recurrence by 2.5-fold vs. Oncotype...
02:28 , Dec 16, 2008 |  BC Extra  |  Clinical News

bioTheranostics, Genomic Health report data

bioTheranostics (San Diego, Calif.) said data from tissue samples from 166 estrogen receptor-positive breast cancer patients showed that the company's Theros Breast Cancer Index (BCI) reduced the number of patients classified as having an intermediate...